Utah Medical Products Inc. (UTMD) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, UTMD scores 62 out of 100, a letter grade of C, with the verdict label "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

• Fundamental Cash Engine: 17 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 26.9% and an FCF yield of 6.73%. This is the strongest pillar and suggests the business generates returns well above a typical cost of capital relative to the capital it employs, with a meaningful share of market value returned as free cash flow.
• Whale / 13F Flow: 6 / 20. Per the Roarable RQD rating, this pillar measures institutional accumulation and options positioning. The low score indicates limited institutional-flow support in the source data, a factor that can leave a stock more sensitive to its own tape.
• Insider Conviction: 15 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. A moderately positive reading is consistent with the insider purchase headline in the news wire (see Recent Catalysts).
• Macro Regime Fit: 11 / 20. Per the Roarable RQD rating, beta is 1.0 and the pillar reflects sector sensitivity. The score implies the stock tracks broad market swings without a clear defensive or cyclical edge.
• Forensic Balance Sheet: 13 / 20. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 4/9, and Debt/Equity is 0.5. These figures sit in a middle band: not distressed, but not showing strong forensic scores.

Taken together, the rating points to a business with high capital efficiency and cash generation, offset by weak institutional flow and middling balance-sheet and macro-fit scores. For a prospective investor, the upside case rests on the cash-return profile; the valuation tradeoff is that an EV/EBITDA of 10.8 and a 6.73% FCF yield must be weighed against declining reported revenue in the SEC financials (see Financial Trend). The Hold verdict signals balanced rather than asymmetric risk-reward at the current price.

Per the SEC financials, revenue declined from $50.2M (FY 2023) to $40.9M (FY 2024) and $38.5M (FY 2025), while operating income fell from $16.8M to $11.4M over the same span. Per the market data, net margin is 0%, and per the SEC financials net income is reported as $0.0M in each period. Per the Roarable RQD rating, ROIC is 26.9%, the Altman Z-Score is 2.5, and the Piotroski F-Score is 4/9. Per the SEC financials, cash rose from $83.0M to $85.8M, and debt is listed as N/A in the reported periods.

Per the news wire, the dominant catalyst is a tender offer process, with headlines reporting that the tender offer was extended, that results of the tender offer were reported, that corrected results were issued, and that a $75-per-share offer had an effective cost of $75.36 per share. Per the news wire, a Benzinga report describes an insider, Kevin L Cornwell, purchasing approximately $66K in stock. A separate headline reports Q3 results highlighting revenue pressure beneath strong margins. The news wire items are all tagged YELLOW with impact label MARKET WIRE.

Risk watch items per the news wire include the revenue pressure noted in the Q3 headline and the need to monitor corrected tender-offer figures. Per the Butterfly Supply-Chain Graph, the supply chain is marked NONE, no butterfly links are present, and no proprietary signals are present.

• What is the current status and final terms of the tender offer referenced in the news wire, and how do the "corrected results" change the reported figures?
• Why is net income reported as $0.0M and EPS as N/A across all periods, and what drives the 0% net margin against a 29.6% operating margin?
• What are the reported debt figures, since debt is listed as N/A in every period?
• What explains the revenue decline from $50.2M to $38.5M over two years, and is the Q3 revenue pressure expected to continue?
• What are the trailing and forward earnings figures, given that P/E and EPS are unavailable in the source data?